newsfilter
← Latest News
PR Newswire·

Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting

  • Eli Lilly & Co. launched the "Life Doesn't Slow Down" campaign for Foundayo (orforglipron) with comedian Leanne Morgan as a paid spokesperson & patient.
  • Foundayo is a once-daily prescription GLP-1 pill approved by the FDA in April 2026 to help adults with obesity or overweight with weight-related medical problems lose weight.
  • Clinical studies showed adults with obesity lost up to 25 pounds (11%) at the 17.2 mg dose when combined with a reduced-calorie diet & increased physical activity.
  • Foundayo is not indicated for cosmetic weight loss, & individual results may vary based on dosage & medical history.
  • The medication carries a boxed warning for thyroid tumors, including thyroid cancer, & should not be used by patients with a history of medullary thyroid carcinoma or MEN 2.
  • Common side effects include nausea, constipation, diarrhea, vomiting, abdominal pain, headache, hair loss, & gas.
  • Serious risks include pancreatitis, severe stomach problems, kidney injury from dehydration, low blood sugar, serious allergic reactions, gallbladder issues, & vision changes in diabetics.
  • Foundayo should not be taken with other GLP-1 receptor agonists, & its safety in children remains unknown.
  • The drug is available via LillyDirect home delivery, retail pharmacies, & telehealth providers with pricing options ranging from $25 to $149 per month depending on insurance status.
  • Patients taking oral birth control are advised to use an alternative method for 30 days after starting treatment or increasing the dose.
  • Foundayo is being studied for additional conditions beyond weight management, including type 2 diabetes, obstructive sleep apnea, osteoarthritis, hypertension, peripheral artery disease, & stress urinary incontinence.
Company
Eli Lilly and Company
Keywords
Eli Lilly and Company